Compass Therapeutics, Inc. has received a deficiency notice from Nasdaq regarding its stock price, which has fallen below the minimum requirement for continued listing. This situation raises concerns not only for the company but also for the broader biological products industry, where maintaining stock price is essential.

On November 19, 2026, Compass Therapeutics, which trades under the ticker symbol CMPX on the Nasdaq, was informed that its stock price had not met the minimum bid price requirement of $1.00 per share for the past 30 consecutive business days. This notification, issued by the Nasdaq Listing Qualifications Department, indicates that the company must take action to avoid potential delisting.

Background

Compass Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, primarily focused on the development of biological products. The company was formerly known as Olivia Ventures, Inc. and has been operating under its current name since April 2018. Compass Therapeutics is categorized under the SIC code 2836, which pertains to biological products (no diagnostic substances). The company is classified as a smaller reporting company and is listed on the Nasdaq Capital Market.

What the Filing Says

According to the filing dated November 20, 2026, "the Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol 'CMPX' at this time." The company has been granted a 180-day period, until May 18, 2027, to regain compliance with the minimum bid price requirement. If the stock price reaches $1.00 or more for at least 10 consecutive business days before this deadline, the company will be considered compliant.

Impact

This situation may affect various stakeholders, including investors, employees, and partners of Compass Therapeutics. The company's ability to maintain its listing on Nasdaq is crucial for its credibility and ability to attract investment. Additionally, the potential for delisting could impact employee morale and retention, as well as the company's partnerships within the biotechnology sector.

What's Next

Compass Therapeutics intends to monitor its stock price closely and may consider options to regain compliance, including a reverse stock split if necessary. However, the filing does not specify what further actions will be taken beyond monitoring the situation. The company has until May 18, 2027, to demonstrate compliance with Nasdaq's requirements.